HeartFlow vs ManageMR

The HeartFlow® mobile app is a convenient way for clinician customers to see the status of their patients’ HeartFlow FFRct Analyses. Quickly scan a list of patients in your institution with the HeartFlow Analysis and view patients’ personalized 3D models with FFRct values. If you are not currently a HeartFlow customer but are curious to try the HeartFlow Analysis, you can still preview the 3D model in a quick introduction experience. Note: Important differences exist in how FFRct values are presented in the mobile app. Please contact HeartFlow Support (support@heartflow.com) with any questions. http://www.heartflow.com **** About HeartFlow: HeartFlow is transforming the way cardiovascular disease is diagnosed and treated. Our HeartFlow FFRct Analysis is a non-invasive cardiac test that creates a personalized 3D model of the heart. Clinicians use this analysis to evaluate blood flow to the heart and to help them determine the appropriate treatment pathway for each patient with suspected coronary artery disease (CAD). Why the HeartFlow Analysis matters: • Regulated medical device with FDA 510(k) clearance, CE mark and PMDA approval. • Substantial clinical evidence with more than 500 peer-reviewed articles • Centers for Medicare and Medicaid Services (CMS) approved reimbursement in the US • Recommended by NICE and mandated by NHS England and NHS Improvement through the MedTech Funding Mandate • Over 235 million patients in the US have access to the HeartFlow Analysis through their current health insurance • Improves clinical outcomes through earlier detection of CAD without intervention or adverse events - 83% reduction in unnecessary angiograms* • Helps reduce the overall cost of care - 26% reduction based on the mean one-year per-patient cost* • Leverages deep learning for product improvements in accuracy and turnaround time • Improves the overall patient experience and quality of life* - hear from a few of the more than 100,000 patients touched by HeartFlow on our web site The HeartFlow FFRct Analysis is commercially available in the United States, Canada, Europe, and Japan. The HeartFlow Mobile Application is only commercially available in the United States, Canada, and the UK. Don’t have HeartFlow at your institution? Submit a request, and we’ll help get the conversation started. http://www.heartflow.com/contact-us * Douglas, et al. J Am Coll Cardiol 2016; 68:435-45.

This clinical decision support app provides clinicians with personalized referral and treatment advice for diagnosed mitral regurgitation patients by verifying the severity and etiology of the MR. • Enter patient parameters from an echo assessment. • Review customized advice on - Probable severity and etiology of a patient’s MR - Need for referral - Feasibility of mitral valve repair vs. replacement for the patient Content in this app is derived from the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation. The information and recommendations in this clinical decision support app are not meant to represent the only or best course of care nor replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.